Inhibitors of glutaminyl cyclase
Compounds that act as inhibitors of QC including those represented by the general formulae 1 to 9: and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Corea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
1. A method of treatment of Alzheimer's disease comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of formula 2a or a pharmaceuticaly acceptable salt or stereoisomer thereof:
wherein:
A is selected from the group consisting of:
wherein
R 6 -R 10 are H or methyl;
n and n 1 are 1;
and
B is
wherein:
D represents substituted phenyl, wherein the substitutent is -oxyalkyl, -thioalkyl, or halogenyl; or D represents dihydrobenzodioxine, benzodioxole, benzodithiole dihydrobenzodithiine, benzooxathiole or dihydorbenzooxathiine; and
X represents O, S, or N—CN.
2. A method of treatment of Alzheimer's disease comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition for parenteral, enteral or oral administration, comprising at least one compound of formula 2a or a pharmaceuticaly acceptable salt or stereoisomer thereof, optionally in combination with a therapeutically acceptable carrier or excipient:
wherein:
A is selected from the group consisting of:
wherein
R 6 -R 10 are H or methyl;
n and n 1 are 1;
and
B is
wherein:
D represents substituted phenyl, wherein the substitutent is -oxyalkyl, -thioalkyl, or halogenyl; or D represents dihydrobenzodioxine, benzodioxole, benzodithiole dihydrobenzodithiine, benzooxathiole or dihydorbenzooxathiine; and
X represents O, S, or N—CN.
3. A method of treatment of Alzheimer's disease comprising administering to a mammal in a need thereof a therapeutically effective amount of a pharmaceutical composition comprising (i) at least one compound of formula 2a or a pharmaceuticaly acceptable salt or stereoisomer thereof and (ii) at least one agent selected from the group consisting of PEP-inhibitors, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY antagonists and ACE inhibitors; optionally in combination with a therapeutically acceptable carrier or excipient:
wherein:
A is selected from the group consisting of:
wherein
R 6 -R 10 are H or methyl;
n and n 1 are 1;
and
B is
wherein:
D represents substituted phenyl, wherein the substitutent is -oxyalkyl, -thioalkyl, or halogenyl; or D represents dihydrobenzodioxine, benzodioxole, benzodithiole dihydrobenzodithiine, benzooxathiole or dihydorbenzooxathiine; and
X represents O, S, or N—CN.
4. The method according to claim 1 , wherein R 6 -R 10 are H.
5. The method according to claim 1 , wherein X is S.
6. The method according to claim 4 , wherein X is S.
7. The method according to claim 1 , wherein D is 3,4-(dimethoxy)-phenyl.
8. The method according to claim 4 , wherein D is 3,4-(dimethoxy)-phenyl.
9. The method according to claim 5 , wherein D is 3,4-(dimethoxy)-phenyl.
10. The method according to claim 6 , wherein D is 3,4-(dimethoxy)-phenyl.
11. The method according to claim 1 , wherein the compound of formula 2a is selected from the group consisting of:
or a pharmaceuticaly acceptable salt or stereoisomer thereof.
12. The method according to claim 3 , wherein said inhibitor of DP IV/DP IV-like enzymes is selected from the group consisting of L-threo-isoleucyl pyrrolidide, L-allo-isoleucyl thiazolidide, L-allo-isoleucyl pyrrolidide; and salts thereof or valine pyrrolidide, NVP-DPP728A (1-[[[2-[{5-cyanopyridin-2-yl}amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrro-lidine) LAF-237 (1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine -2(S)-carbonitrile); TSL-225 (tryptophyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid), FE-999011 ([(2S)-1-([2'S]-2'-amino-3',3'dimethyl-butanoyl)-pyrrolidine-2-carbonitrile]), GW-229A, 815541, MK-431 and PT-100 (Point Therapeutics).
13. The method according to claim 3 , wherein said NPY antagonist is selected from the group consisting of 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine, BIBP3226 and (R)-N2-(diphenylacetyl)-(R)-N-[1-(4-hydroxy-phenyl)ethyl]arginine amide.
14. The method according to claim 3 , wherein said PEP-inhibitor is selected from the group consisting of chemical derivatives of proline or small peptides containing terminal prolines, e.g. benzyloxycarbonyl-prolyl-prolinal, N-terminal substituted L-proline or L-prolylpyrrolidine, substituted N-benzyloxycarbonyl (Z) dipeptides containing prolinal at the carboxy terminus, substituted thioprolines, substituted thiazolidines, substituted oxopyrrolidines, carboxy terminal modified prolines including fluorinated ketone derivatives, chloromethyl ketone derivatives of acyl-proline or acylpeptide-proline (Z-Gly-Pro-CH 2 Cl) and 2-acylpyrrolidine derivatives.
15. The method according to claim 3 , wherein said PEP-inhibitor is selected from the group consisting of Fmoc-Ala-Pyrr-CN, Z-321, ONO-1603, JTP-4819 and S-17092.
16. The method according to claim 3 , wherein said ACE-inhibitor is SDZ ENA 713 (rivastigmine (+)-(S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenylcarbamate hydrogen tartrate).
17. The method according to claim 1 , wherein X represents S or N—CN.
18. The method according to claim 3 , wherein X represents S or N—CN.